Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis

Fig. 7

Wedelolactone inhibits bladder cancer growth in vitro and in vivo. A and B CCK-8 assay to evaluate the proliferation of 5637 and T24 cells treated with different compounds. C and D Colony formation of 5637 and T24 cells treated with wedelolactone. The number of colonies formed was counted by ImageJ. E and F Flow cytometry analysis of apoptosis in 5637 and T24 cells treated with wedelolactone. G and H Flow cytometry was performed to detect TRPV2 expression on the membranes of 5637 and T24 cells treated with wedelolactone. I and J. Flow cytometry was performed to detect intracellular Ca2+ levels in T24 cells treated with wedelolactone. K and L. Representative photographs of 5637 tumors implanted in mice treated with vehicle or wedelolactone. Tumor weight was analyzed (n = 8). M and N Representative photographs of T24 tumors implanted in mice treated with vehicle or wedelolactone. Tumor weight was analyzed (n = 7). O and P H&E staining of 5637 tumor tissues or T24 tumor tissues from tumor-bearing mice treated with wedelolactone or vehicle. Q and R TUNEL assay of 5637 tumor tissue or T24 tumor tissue from tumor-bearing mice treated with wedelolactone or vehicle

Back to article page